Korea United Pharm Inc. (033270.KS)
KRW 18480.0
(-1.75%)
KRW 18480.0
(-1.75%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 10.96 Billion KRW | 33.18% |
| 2022 | 8.23 Billion KRW | -36.54% |
| 2021 | 12.97 Billion KRW | 13.92% |
| 2020 | 11.38 Billion KRW | -4.2% |
| 2019 | 11.88 Billion KRW | 78.72% |
| 2018 | 6.65 Billion KRW | -5.0% |
| 2017 | 7 Billion KRW | -33.79% |
| 2016 | 10.57 Billion KRW | -21.06% |
| 2015 | 13.39 Billion KRW | -32.29% |
| 2014 | 19.77 Billion KRW | 8.04% |
| 2013 | 18.3 Billion KRW | 71.25% |
| 2012 | 10.69 Billion KRW | 16.91% |
| 2011 | 9.14 Billion KRW | 47.46% |
| 2010 | 6.2 Billion KRW | 5.49% |
| 2009 | 5.87 Billion KRW | 72.25% |
| 2008 | 3.41 Billion KRW | 44.04% |
| 2007 | 2.36 Billion KRW | 176.99% |
| 2006 | 855.4 Million KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 10.52 Billion KRW | -3.99% |
| 2024 Q2 | 13.68 Billion KRW | 30.05% |
| 2023 Q4 | 10.96 Billion KRW | 38.99% |
| 2023 Q2 | 9.39 Billion KRW | 39.97% |
| 2023 FY | 10.96 Billion KRW | 33.18% |
| 2023 Q1 | 6.71 Billion KRW | -18.42% |
| 2023 Q3 | 7.88 Billion KRW | -16.09% |
| 2022 Q3 | 9.74 Billion KRW | -13.61% |
| 2022 Q1 | 11.61 Billion KRW | -10.47% |
| 2022 FY | 8.23 Billion KRW | -36.54% |
| 2022 Q2 | 11.28 Billion KRW | -2.84% |
| 2022 Q4 | 8.23 Billion KRW | -15.55% |
| 2021 Q4 | 12.97 Billion KRW | -9.36% |
| 2021 FY | 12.97 Billion KRW | 13.92% |
| 2021 Q1 | 14.18 Billion KRW | 24.58% |
| 2021 Q2 | 12.82 Billion KRW | -9.56% |
| 2021 Q3 | 14.3 Billion KRW | 11.54% |
| 2020 FY | 11.38 Billion KRW | -4.2% |
| 2020 Q1 | 11.14 Billion KRW | -6.24% |
| 2020 Q3 | 12.33 Billion KRW | -7.19% |
| 2020 Q4 | 11.38 Billion KRW | -7.66% |
| 2020 Q2 | 13.28 Billion KRW | 19.24% |
| 2019 Q4 | 11.88 Billion KRW | -5.89% |
| 2019 FY | 11.88 Billion KRW | 78.72% |
| 2019 Q1 | 7.42 Billion KRW | 11.67% |
| 2019 Q2 | 7.04 Billion KRW | -5.08% |
| 2019 Q3 | 12.62 Billion KRW | 79.16% |
| 2018 Q3 | 4.75 Billion KRW | -13.64% |
| 2018 Q1 | 6.25 Billion KRW | -10.71% |
| 2018 Q2 | 5.5 Billion KRW | -12.0% |
| 2018 FY | 6.65 Billion KRW | -5.0% |
| 2018 Q4 | 6.65 Billion KRW | 40.0% |
| 2017 Q1 | 9.82 Billion KRW | -7.09% |
| 2017 Q4 | 7 Billion KRW | -43.19% |
| 2017 Q3 | 12.32 Billion KRW | 35.82% |
| 2017 Q2 | 9.07 Billion KRW | -7.64% |
| 2017 FY | 7 Billion KRW | -33.79% |
| 2016 Q1 | 12.64 Billion KRW | 0.0% |
| 2016 Q4 | 10.57 Billion KRW | 32.78% |
| 2016 Q3 | 7.96 Billion KRW | -8.61% |
| 2016 Q2 | 8.71 Billion KRW | -31.09% |
| 2016 FY | 10.57 Billion KRW | -21.06% |
| 2015 Q2 | 19.58 Billion KRW | -0.49% |
| 2015 Q1 | 19.68 Billion KRW | -0.49% |
| 2015 Q3 | 17.13 Billion KRW | -12.53% |
| 2015 FY | 13.39 Billion KRW | -32.29% |
| 2014 Q1 | 21.3 Billion KRW | 16.38% |
| 2014 Q2 | 24.21 Billion KRW | 13.65% |
| 2014 FY | 19.77 Billion KRW | 8.04% |
| 2014 Q4 | 19.77 Billion KRW | -17.41% |
| 2014 Q3 | 23.94 Billion KRW | -1.1% |
| 2013 FY | 18.3 Billion KRW | 71.25% |
| 2013 Q2 | 12.1 Billion KRW | 14.89% |
| 2013 Q1 | 10.53 Billion KRW | -1.41% |
| 2013 Q4 | 18.3 Billion KRW | 53.1% |
| 2013 Q3 | 11.95 Billion KRW | -1.25% |
| 2012 Q4 | 10.69 Billion KRW | 0.0% |
| 2012 FY | 10.69 Billion KRW | 16.91% |
| 2012 Q1 | 8.97 Billion KRW | 0.0% |
| 2011 Q1 | 8.09 Billion KRW | 30.53% |
| 2011 Q2 | 10.69 Billion KRW | 32.13% |
| 2011 Q3 | 10.52 Billion KRW | -1.59% |
| 2011 FY | 9.14 Billion KRW | 47.46% |
| 2010 Q4 | 6.2 Billion KRW | 33.05% |
| 2010 Q1 | 5.12 Billion KRW | -12.89% |
| 2010 FY | 6.2 Billion KRW | 5.49% |
| 2010 Q2 | 5.02 Billion KRW | -1.83% |
| 2010 Q3 | 4.66 Billion KRW | -7.29% |
| 2009 Q3 | 4.82 Billion KRW | 35.52% |
| 2009 Q4 | 5.87 Billion KRW | 21.9% |
| 2009 Q2 | 3.55 Billion KRW | -6.36% |
| 2009 Q1 | 3.8 Billion KRW | 11.35% |
| 2009 FY | 5.87 Billion KRW | 72.25% |
| 2008 Q2 | 2.69 Billion KRW | -1.22% |
| 2008 Q3 | 3.48 Billion KRW | 29.17% |
| 2008 Q1 | 2.73 Billion KRW | 0.0% |
| 2008 FY | 3.41 Billion KRW | 44.04% |
| 2008 Q4 | 3.41 Billion KRW | -2.03% |
| 2007 Q2 | 855.4 Million KRW | 0.0% |
| 2007 Q3 | 2.4 Billion KRW | 181.38% |
| 2007 FY | 2.36 Billion KRW | 176.99% |
| 2006 FY | 855.4 Million KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 19.63% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 94.575% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 63.307% |
| HANDOK Inc. | 123.78 Billion KRW | 91.144% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -2204.291% |
| Yuhan Corporation | 60.23 Billion KRW | 81.8% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 93.233% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -10666.783% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 86.636% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -1757.078% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -81.198% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 40.815% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | 12.887% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -585.651% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 19.63% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -9059.965% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 90.94% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 65.742% |
| JW Holdings Corporation | 20.65 Billion KRW | 46.932% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | 26.055% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 63.458% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 63.458% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -4906.599% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -1787.983% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 77.884% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -146.237% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 19.63% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 42.387% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 88.265% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 63.458% |
| Yuhan Corporation | 60.23 Billion KRW | 81.8% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -4.405% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 72.85% |
| Suheung Co., Ltd. | 74 Billion KRW | 85.187% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 63.458% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -163.102% |
| CKD Bio Corp. | 69.43 Billion KRW | 84.211% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 68.293% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 32.027% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -3470.193% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -4906.599% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 84.798% |
| Boryung Corporation | 151.7 Billion KRW | 92.774% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 86.04% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -81.198% |
| JW Lifescience Corporation | 168 Million KRW | -6425.298% |